APG Asset Management US Inc. Takes Position in Zimmer Biomet Holdings, Inc. (NYSE:ZBH)

APG Asset Management US Inc. acquired a new stake in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBHFree Report) during the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund acquired 119,389 shares of the medical equipment provider’s stock, valued at approximately $14,530,000.

A number of other institutional investors and hedge funds have also modified their holdings of the company. Norges Bank acquired a new stake in Zimmer Biomet in the 4th quarter valued at $266,896,000. American Century Companies Inc. boosted its stake in Zimmer Biomet by 21.2% in the 3rd quarter. American Century Companies Inc. now owns 4,863,741 shares of the medical equipment provider’s stock valued at $545,809,000 after buying an additional 852,186 shares in the last quarter. Van ECK Associates Corp boosted its stake in Zimmer Biomet by 23.7% in the 4th quarter. Van ECK Associates Corp now owns 2,838,558 shares of the medical equipment provider’s stock valued at $345,452,000 after buying an additional 543,344 shares in the last quarter. Qube Research & Technologies Ltd acquired a new stake in Zimmer Biomet in the 3rd quarter valued at $57,972,000. Finally, Primecap Management Co. CA boosted its stake in Zimmer Biomet by 10.5% in the 4th quarter. Primecap Management Co. CA now owns 5,086,578 shares of the medical equipment provider’s stock valued at $619,037,000 after buying an additional 484,151 shares in the last quarter. 88.89% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

Several analysts recently commented on ZBH shares. Evercore ISI boosted their price target on Zimmer Biomet from $125.00 to $130.00 and gave the company an “in-line” rating in a research note on Thursday, April 4th. The Goldman Sachs Group started coverage on Zimmer Biomet in a research note on Thursday, May 30th. They issued a “neutral” rating and a $129.00 price target on the stock. Truist Financial decreased their price target on Zimmer Biomet from $137.00 to $130.00 and set a “hold” rating on the stock in a research note on Friday, May 3rd. JPMorgan Chase & Co. boosted their price objective on Zimmer Biomet from $115.00 to $125.00 and gave the stock a “neutral” rating in a research note on Friday, February 9th. Finally, Citigroup boosted their price objective on Zimmer Biomet from $134.00 to $140.00 and gave the stock a “neutral” rating in a research note on Wednesday, April 3rd. One equities research analyst has rated the stock with a sell rating, nine have given a hold rating and seven have assigned a buy rating to the company’s stock. According to MarketBeat.com, Zimmer Biomet has an average rating of “Hold” and a consensus price target of $133.75.

Check Out Our Latest Analysis on ZBH

Zimmer Biomet Trading Down 1.8 %

Shares of ZBH opened at $113.12 on Tuesday. The company has a quick ratio of 0.80, a current ratio of 1.66 and a debt-to-equity ratio of 0.38. Zimmer Biomet Holdings, Inc. has a 12-month low of $102.00 and a 12-month high of $147.50. The firm has a market capitalization of $23.27 billion, a PE ratio of 24.48, a price-to-earnings-growth ratio of 2.07 and a beta of 1.02. The stock’s fifty day simple moving average is $122.04 and its 200-day simple moving average is $122.05.

Zimmer Biomet (NYSE:ZBHGet Free Report) last issued its quarterly earnings results on Thursday, May 2nd. The medical equipment provider reported $1.94 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.87 by $0.07. Zimmer Biomet had a return on equity of 12.70% and a net margin of 12.93%. The business had revenue of $1.89 billion for the quarter, compared to analyst estimates of $1.87 billion. During the same quarter in the prior year, the firm posted $1.89 earnings per share. The firm’s revenue for the quarter was up 3.2% compared to the same quarter last year. As a group, research analysts predict that Zimmer Biomet Holdings, Inc. will post 8.1 earnings per share for the current year.

Zimmer Biomet Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, July 31st. Investors of record on Wednesday, June 26th will be issued a $0.24 dividend. The ex-dividend date of this dividend is Wednesday, June 26th. This represents a $0.96 dividend on an annualized basis and a yield of 0.85%. Zimmer Biomet’s dividend payout ratio is presently 20.78%.

Zimmer Biomet Profile

(Free Report)

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.

See Also

Want to see what other hedge funds are holding ZBH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zimmer Biomet Holdings, Inc. (NYSE:ZBHFree Report).

Institutional Ownership by Quarter for Zimmer Biomet (NYSE:ZBH)

Receive News & Ratings for Zimmer Biomet Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zimmer Biomet and related companies with MarketBeat.com's FREE daily email newsletter.